PemBla
Research type
Research Study
Full title
A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer
IRAS ID
209428
Contact name
Andrew Protheroe
Contact email
Sponsor organisation
Joint Research Office, Oxford University Hospitals NHS Foundation Trust
Eudract number
2016-002267-33
Duration of Study in the UK
4 years, 0 months, 0 days
Research summary
Bladder cancer is the seventh most common cancer in the UK and ninth most common cancer worldwide. New strategies for treating this disease are urgently required to reduce recurrence and progression rates.
Pembrolizumab is a type of immunotherapy drug that has been approved for use in certain types of melanoma and lung cancer. It is thought to work by helping the body’s immune system to recognise and attack cancer. Drugs that work in a similar way have shown some encouraging results in studies treating patients with bladder cancer that has spread to other parts of the body, although they are not currently approved for treating either advanced or localised bladder cancer.
This trial is being performed to assess the safety and tolerability of giving pembrolizumab to patients with localised bladder cancer and to study what effects the drug has on the tumour; Participants will have all but one tumour (referred to as the marker lesion) removed during their transurethral resection of bladder tumour (TURBT) procedure at the start of the trial. After trial treatment, a further TURBT procedure will be carried out to remove the marker lesion, or if the marker lesion is no longer visible, a biopsy will be taken of the area where the growth was before.
After a safety run in, the trial will test two different ways of giving the pembrolizumab; directly into the bladder (intravesical) with 6 doses being received over 6 weeks and with a further dose approximately 3 weeks later, or into the blood stream via the veins (intravenous) with a dose being received every 3 weeks for a maximum of 4 doses. 36 eligible participants from across 3 UK centres will be randomly allocated to receive treatment by one of these ways.
Following the end of treatment visit, patients will return to receiving standard care but receive follow-up for up to 2 years.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
17/SC/0121
Date of REC Opinion
13 Jun 2017
REC opinion
Further Information Favourable Opinion